Next Article in Journal
Moving forward with New Data and Approaches: A Fresh Look at Anthracyclines in Non-Hodgkin’s Lymphoma
Previous Article in Journal
The OnControl Bone Marrow Biopsy Technique Is Superior to the Standard Manual Technique for Hematologists-In-Training: A Prospective, Rrandomized Comparison
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Total Remission of Severe Immune Thrombocytopenia after Short Term Treatment with Romiplostim

by
Efthymia Vlachaki
*,
Vaia Papageorgiou
,
Filippos Klonizakis
,
Maria Spandonidou
,
Sofia Chisan
,
Evaggelia Vetsiou
and
Elissavet Ioannidou
Second Department of Internal Medicine, Hematological Laboratory, Aristotle University, Hippokrateon General Hospital, Amorgou 29 Street, 55337 Thessaloniki, Greece.
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2011, 3(3), e20; https://doi.org/10.4081/hr.2011.e20
Submission received: 26 July 2011 / Revised: 12 October 2011 / Accepted: 26 July 2011 / Published: 27 October 2011

Abstract

Immune thrombocytopenia (ITP) in adults is an acquired chronic immune-mediated disorder defined by isolated thrombocytopenia. In recent years, an improved understanding of the pathophysiology of ITP has been achieved and it is now accepted that the disorder is due to increased platelet destruction and decreased platelet production from megakaryocytes. Thrombopoietin (TPO)-receptor agonists (romiplostim and eltrombopag) are new therapeutic modalities in the treatment of ITP. Here we describe a case of an elderly patient with severe ITP who presented complete remission after short-term use of romiplostim (only 3 weekly doses). This finding is quite interesting as the TPO-receptor agonists are, so far, believed to rarely lead to off-treatment sustained remission. The common notion of long-term use of romiplostim could be reexamined in future studies. Furthermore, the short term treatment with romiplostim may reduce the cost and the risk of side effects.
Keywords: immune thrombocytopenia; thrombopoietin-receptor agonists; romiplostim immune thrombocytopenia; thrombopoietin-receptor agonists; romiplostim

Share and Cite

MDPI and ACS Style

Vlachaki, E.; Papageorgiou, V.; Klonizakis, F.; Spandonidou, M.; Chisan, S.; Vetsiou, E.; Ioannidou, E. Total Remission of Severe Immune Thrombocytopenia after Short Term Treatment with Romiplostim. Hematol. Rep. 2011, 3, e20. https://doi.org/10.4081/hr.2011.e20

AMA Style

Vlachaki E, Papageorgiou V, Klonizakis F, Spandonidou M, Chisan S, Vetsiou E, Ioannidou E. Total Remission of Severe Immune Thrombocytopenia after Short Term Treatment with Romiplostim. Hematology Reports. 2011; 3(3):e20. https://doi.org/10.4081/hr.2011.e20

Chicago/Turabian Style

Vlachaki, Efthymia, Vaia Papageorgiou, Filippos Klonizakis, Maria Spandonidou, Sofia Chisan, Evaggelia Vetsiou, and Elissavet Ioannidou. 2011. "Total Remission of Severe Immune Thrombocytopenia after Short Term Treatment with Romiplostim" Hematology Reports 3, no. 3: e20. https://doi.org/10.4081/hr.2011.e20

Article Metrics

Back to TopTop